Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., filed a Form 4 on November 17, 2026, reporting the disposition of common stock and cancellation of stock options in connection with the acquisition of Pacira BioSciences by Viatris Inc.

Key Highlights

  • Shares disposed: 216,729.67 shares of Pacira BioSciences common stock were disposed of on November 17, 2026, at a price of $36.50 per share.
  • Merger trigger: The disposition occurred pursuant to the Agreement and Plan of Merger dated October 8, 2026, among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc.
  • Merger outcome: Pacira BioSciences continued as the surviving corporation and became a wholly owned subsidiary of Viatris following the merger.
  • Six stock options canceled: Options covering a combined 121,937 shares with exercise prices ranging from $32.07 to $60.96 per share were disposed of at the effective time of the merger.
  • Post-transaction ownership: Following the reported transactions, Slonin's directly held common stock and all six option positions show zero remaining beneficial ownership.
  • ESPP shares included: The disposed share total includes 346.024 shares acquired under the issuer's Amended and Restated 2014 Employee Stock Purchase Plan in November 2026.

Slonin's Holdings Canceled at Viatris Merger Effective Time

According to the filing, Jonathan Slonin, identified as Chief Medical Officer of Pacira BioSciences, Inc. (NASDAQ:PCRX), disposed of 216,729.67 shares of common stock on November 17, 2026, at the offer price of $36.50 per share. The filing states this disposition occurred pursuant to the Agreement and Plan of Merger dated October 8, 2026, under which Peach Purchaser Sub Inc. consummated a cash tender offer to purchase all outstanding shares of Pacira BioSciences common stock at $36.50 per share, net of applicable withholding taxes and without interest. At the effective time of the merger on November 17, 2026, each share was converted into the right to receive the offer price, and Pacira BioSciences became a wholly owned subsidiary of Viatris Inc.

The filing notes that the disposed share total includes 346.024 shares acquired under the issuer's Amended and Restated 2014 Employee Stock Purchase Plan in November 2026, as well as restricted stock unit awards. The filing states that at the effective time, each outstanding RSU, whether vested or unvested, "was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings."

Six stock options were also reported as disposed of at the merger's effective time. These covered 35,500 shares at an exercise price of $52.37, 14,137 shares at $60.96, 10,000 shares at $60.79, 24,800 shares at $59.39, 27,500 shares at $38.74, and 10,000 shares at $32.07, with expiration dates ranging from July 2, 2030 to January 3, 2034. The filing states that each option with a per-share exercise price greater than or equal to the $36.50 offer price "was cancelled at the Effective Time with no consideration payable." All six option positions show zero beneficial ownership following the transactions.

What Was Disclosed

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reported the full disposition of his common stock holdings and the cancellation of six stock option awards, all resulting from the November 17, 2026, effective time of the merger between Pacira BioSciences and Viatris Inc.